Literature DB >> 27262824

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.

Takuya Wakamiya1, Tatsunori Hokosaki1, Shin-Ichi Tsujimoto1, Keisuke Kadota1, Yusuke Nakano1, Shigeo Watanabe1, Mari Iwamoto1, Masakatsu Yanagimachi2, Shuichi Ito1.   

Abstract

BACKGROUND: Warfarin dosage requirements show considerable inter-individual variability. There are some reports of warfarin dose regimens correlating with single nucleotide polymorphisms (SNP) for CYP2C9, VKORC1 and other genes in adults. In children, however, reports are scarcer than in adults and the number of genes examined is more limited. We explored the effects of genetic variation on warfarin dose requirement in Japanese pediatric patients.
METHODS: A total of 45 patients who were prescribed warfarin at the Yokohama City University Hospital were included in this study. The influence of genetic polymorphisms on stable warfarin dosage requirement was investigated by genotyping SNPs of the VKORC1, CYP2C9, CYP4F2, and GGCX genes (rs9923231, rs1057910, rs2108622, and rs699664, respectively) in each patient.
RESULTS: Patients with the TT genotype in rs9923231 in VKORC1 required significantly lower maintenance dosages than those with the TC genotype (p = 0.001). Multiple regression analysis showed that, while VKORC1 status and patient height account for 78.2 % of the variability in maintenance warfarin dosage, genetic polymorphisms in VKORC1 account for 27 %, although polymorphisms in CYP4F2 and GGCX had no effect on dosage and the effect of CYP2C9 could not be evaluated.
CONCLUSIONS: Polymorphisms in VKORC1 partially affected daily warfarin dosage requirements. VKORC1 genotype and height are the primary determinants influencing warfarin dosage in Japanese pediatric patients. Further studies with larger sample sizes are needed to confirm our results.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27262824     DOI: 10.1007/s40291-016-0212-5

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  22 in total

1.  Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.

Authors:  Yuya Kato; Fukiko Ichida; Kazuyoshi Saito; Kazuhiro Watanabe; Keiichi Hirono; Toshio Miyawaki; Naoki Yoshimura; Isao Horiuchi; Masato Taguchi; Yukiya Hashimoto
Journal:  Drug Metab Pharmacokinet       Date:  2011-01-25       Impact factor: 3.614

2.  VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Authors:  Tina T Biss; Peter J Avery; Leonardo R Brandão; Elizabeth A Chalmers; Michael D Williams; John D Grainger; Julian B S Leathart; John P Hanley; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

Review 3.  Recent advances in cardiac surgery.

Authors:  W I Norwood; J D Pigott
Journal:  Pediatr Clin North Am       Date:  1985-10       Impact factor: 3.278

4.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

5.  Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.

Authors:  Ruijuan Liang; Chunling Wang; Hong Zhao; Jie Huang; Dayi Hu; Yihong Sun
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

6.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

7.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

8.  Genetic and clinical determinants influencing warfarin dosing in children with heart disease.

Authors:  Nguyenvu Nguyen; Peter Anley; Margaret Y Yu; Gang Zhang; Alexis A Thompson; Larry J Jennings
Journal:  Pediatr Cardiol       Date:  2012-11-25       Impact factor: 1.655

Review 9.  Kawasaki disease.

Authors:  Tomisaku Kawasaki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2006-04       Impact factor: 3.493

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  4 in total

1.  Pharmacogenetic-Guided Algorithm to Improve Daily Dose of Warfarin in Elder Han-Chinese Population.

Authors:  Yirong Ren; Chenguang Yang; Hao Chen; Dapeng Dai; Yan Wang; Huolan Zhu; Fang Wang
Journal:  Front Pharmacol       Date:  2020-07-10       Impact factor: 5.810

Review 2.  GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations.

Authors:  Eva Y G De Vilder; Jens Debacker; Olivier M Vanakker
Journal:  Int J Mol Sci       Date:  2017-01-25       Impact factor: 5.923

3.  Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.

Authors:  Jubby Marcela Galvez; Carlos Martin Restrepo; Nora Constanza Contreras; Clara Alvarado; Carlos-Alberto Calderón-Ospina; Nidia Peña; Ricardo A Cifuentes; Daniela Duarte; Paul Laissue; Dora Janeth Fonseca
Journal:  Pharmgenomics Pers Med       Date:  2018-10-16

4.  The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies.

Authors:  Taofik Rusdiana; Yanni D Mardhiani; Norisca A Putriana; Dolih Gozali; Daisuke Nagano; Takuya Araki; Koujirou Yamamoto
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.